Advanced in Pseudomyxoma Peritonei

Dr. Natalie S. Godbee

Gynecologic Oncology | Oncology
City Of Hope Medical Group Of Georgia LLC
600 Celebrate Life Pkwy, 
Newnan, GA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Advanced in Pseudomyxoma Peritonei
City Of Hope Medical Group Of Georgia LLC
600 Celebrate Life Pkwy, 
Newnan, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Natalie Godbee is a Gynecologic Oncologist and an Oncologist in Newnan, Georgia. Dr. Godbee is rated as an Advanced provider by MediFind in the treatment of Pseudomyxoma Peritonei. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Testicular Yolk Sac Tumor, and Ovarian Carcinosarcoma. Dr. Godbee is currently accepting new patients.

Her clinical research consists of participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Oncology
Licenses
Obstetrics & Gynecology in PA
Hospital Affiliations
Southeastern Regional Medical Center, Inc
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

CITY OF HOPE MEDICAL GROUP OF GEORGIA LLC
600 Celebrate Life Pkwy, Newnan, GA 30265

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Enrollment Status: Recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Procedure
Study Phase: Not Applicable
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Phase I/II Study of Ruxolitinib With Front-Line Neoadjuvant and Post-Surgical Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase I/II Study of Ruxolitinib With Front-Line Neoadjuvant and Post-Surgical Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Paclitaxel, Ruxolitinib phosphate
Study Phase: Phase 1/Phase 2
A Phase 1 / 2, Open-Label, Multi-Arm Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination With AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors
A Phase 1 / 2, Open-Label, Multi-Arm Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination With AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors
Enrollment Status: Completed
Publish Date: July 05, 2023
Intervention Type: Drug
Study Drugs: AGEN-2034 PD-1 Antibody, AGEN-1884 CTLA4 Antibody
Study Phase: Phase 1/Phase 2
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Drug
Study Drugs: VB-111, Paclitaxel
Study Phase: Phase 3
View 6 Less Clinical Trials
Similar Doctors
Advanced in Pseudomyxoma Peritonei
Dr. Meaghan E. Tenney
Gynecologic Oncology | Obstetrics and Gynecology
Advanced in Pseudomyxoma Peritonei
Dr. Meaghan E. Tenney
Gynecologic Oncology | Obstetrics and Gynecology

Northside Surgical Professional Services LLC

960 Johnson Fy Rd Ne, Suite 130, 
Atlanta, GA 
 (40.8 miles away)
404-300-2990
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Meaghan Tenney is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Atlanta, Georgia. Dr. Tenney is rated as a Distinguished provider by MediFind in the treatment of Pseudomyxoma Peritonei. Her top areas of expertise are Ovarian Cancer, Sertoli-Leydig Cell Tumor, Endometrial Cancer, Hysterectomy, and Endoscopy. Dr. Tenney is currently accepting new patients.

Advanced in Pseudomyxoma Peritonei
Dr. Ruchi M. Garg
Gynecologic Oncology | Obstetrics and Gynecology
Advanced in Pseudomyxoma Peritonei
Dr. Ruchi M. Garg
Gynecologic Oncology | Obstetrics and Gynecology
600 Celebrate Life Pkwy, 
Newnan, GA 
 (0.1 miles away)
770-400-6000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ruchi Garg is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Newnan, Georgia. Dr. Garg is rated as a Distinguished provider by MediFind in the treatment of Pseudomyxoma Peritonei. Her top areas of expertise are Endometrial Stromal Sarcoma, Malignant Mixed Mullerian Tumor, Endometrial Cancer, Oophorectomy, and Hernia Surgery. Dr. Garg is currently accepting new patients.

Advanced in Pseudomyxoma Peritonei
Dr. Shahin A. Chowdhury
Oncology
Advanced in Pseudomyxoma Peritonei
Dr. Shahin A. Chowdhury
Oncology

City Of Hope Medical Group Of Georgia LLC

600 Celebrate Life Pkwy, 
Newnan, GA 
 (0.1 miles away)
770-400-6080
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Shahin Chowdhury is an Oncologist in Newnan, Georgia. Dr. Chowdhury is rated as a Distinguished provider by MediFind in the treatment of Pseudomyxoma Peritonei. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Lynch Syndrome, and Pancreatic Cancer. Dr. Chowdhury is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Godbee's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 13 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile